<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894253</url>
  </required_header>
  <id_info>
    <org_study_id>8263</org_study_id>
    <nct_id>NCT04894253</nct_id>
  </id_info>
  <brief_title>Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus</brief_title>
  <acronym>LUPCELLVAX</acronym>
  <official_title>Study of the Immune Response to SARS-CoV-2 Vaccination in Patients With Systemic Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study the impact of vaccination against Covid-19 on the specific&#xD;
      humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the&#xD;
      pathological immune system of the disease), in a lupus population.&#xD;
&#xD;
      The secondary objective is to study the impact of lupus disease activity on the humoral and&#xD;
      cellular response of patients following vaccination against SARS-CoV-2.&#xD;
&#xD;
      The hypothesis is that disease activity and / or certain treatments used in lupus may&#xD;
      interfere with the humoral and cellular immune response induced by vaccination against&#xD;
      SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Investigation of the immune response following vaccination against SARS-CoV-2</measure>
    <time_frame>3 or 4 weeks</time_frame>
    <description>Collection of clinical data and correlation with immunological analyzes of the biological samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of the immune response following vaccination against SARS-CoV-2</measure>
    <time_frame>3 months</time_frame>
    <description>Collection of clinical data and correlation with immunological analyzes of the biological samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of the immune response following vaccination against SARS-CoV-2</measure>
    <time_frame>6 months</time_frame>
    <description>Collection of clinical data and correlation with immunological analyzes of the biological samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of the immune response following vaccination against SARS-CoV-2</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of clinical data and correlation with immunological analyzes of the biological samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of the immune response following vaccination against SARS-CoV-2</measure>
    <time_frame>18 months</time_frame>
    <description>Collection of clinical data and correlation with immunological analyzes of the biological samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study the impact of lupus disease activity on SARS-CoV-2 vaccine immune response</measure>
    <time_frame>3 or 4 weeks</time_frame>
    <description>Measurement of lupus disease activity by a validated score (SLEDAI) at the time of vaccination and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of lupus disease activity on SARS-CoV-2 vaccine immune response</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of lupus disease activity by a validated score (SLEDAI) at the time of vaccination and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of lupus disease activity on SARS-CoV-2 vaccine immune response</measure>
    <time_frame>6 months</time_frame>
    <description>Measurement of lupus disease activity by a validated score (SLEDAI) at the time of vaccination and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of lupus disease activity on SARS-CoV-2 vaccine immune response</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of lupus disease activity by a validated score (SLEDAI) at the time of vaccination and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of lupus disease activity on SARS-CoV-2 vaccine immune response</measure>
    <time_frame>18 months</time_frame>
    <description>Measurement of lupus disease activity by a validated score (SLEDAI) at the time of vaccination and follow-up.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Systemic Lupus</condition>
  <arm_group>
    <arm_group_label>Single group of 30 patients with systemic lupus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SRAS-CoV-2 vaccination immunological response</intervention_name>
    <description>Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination.&#xD;
Intervention includes immunological analysis on additional volume of blood collected as part of routine care.</description>
    <arm_group_label>Single group of 30 patients with systemic lupus</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood with subsequent extraction of:&#xD;
&#xD;
        -  Serum&#xD;
&#xD;
        -  Peripheral blood mononuclear cell&#xD;
&#xD;
        -  RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic lupus, monitored and vaccinated at the national reference center for&#xD;
        &quot;rare systemic autoimmune diseases&quot; of the University Hospitals of Strasbourg.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subject (â‰¥ 18 years old), male or female&#xD;
&#xD;
          -  Patient with systemic lupus according to ACR 1997 criteria&#xD;
&#xD;
          -  Patient followed by the National Reference Center &quot;Rare Systemic Autoimmune Diseases&quot;&#xD;
             of the University Hospitals of Strasbourg&#xD;
&#xD;
          -  Patient who agreed to be vaccinated against SARS-CoV-2&#xD;
&#xD;
          -  Subject having expressed his non-opposition to the research&#xD;
&#xD;
          -  Subject affiliated to a social health insurance protection scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated by:&#xD;
&#xD;
               -  Corticosteroids (&gt; = 10mg / day)&#xD;
&#xD;
               -  Immunosuppressant (azathioprine, mycophenolate mofetil, cyclophosphamide) to&#xD;
                  control lupus activity&#xD;
&#xD;
               -  A biomedicine targeting B cells (rituximab, belumimab).&#xD;
&#xD;
          -  Inability to provide informed information about the subject (subject in an emergency,&#xD;
             difficulty in understanding the subject, etc.)&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
&#xD;
          -  Subject under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean SIBILIA, MD</last_name>
    <phone>3 88 12 79 55</phone>
    <phone_ext>+33</phone_ext>
    <email>jean.sibilia@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean SIBILIA, Pr</last_name>
      <phone>3 88 12 79 55</phone>
      <phone_ext>+33</phone_ext>
      <email>jean.sibilia@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

